(Q34142678)

31 July 2017

0 references

Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials (English)

1 reference

31 July 2017

0 references

0 references

cardiovascular disease

1 reference

7

O Eyawo

1 reference

31 July 2017

M Briel

10

0 references

Sonal Singh

object named as

S Singh

5

0 references

Gordon Guyatt

8

object named as

G Guyatt

1 reference

31 July 2017

E J Mills

1

1 reference

31 July 2017

P Wu

2

1 reference

31 July 2017

G Chong

3

1 reference

31 July 2017

I Ghement

4

1 reference

31 July 2017

E A Akl

6

1 reference

31 July 2017

O Berwanger

9

1 reference

31 July 2017

language of work or name

English

0 references

publication date

7 October 2010

1 reference

QJM: An International Journal of Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

104

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

109-124

1 reference

Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Over-the-counter sales of statins and other drugs for asymptomatic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Statin therapy and risk of developing type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Coccidioidal infection of the thyroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Systematic review on the risk and benefit of different cholesterol-lowering interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Effect of different antilipidemic agents and diets on mortality: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

The statistical basis of meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Controlling the risk of spurious findings from meta-regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Combination of direct and indirect evidence in mixed treatment comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Inference from Iterative Simulation Using Multiple Sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Interaction of St John's wort with conventional drugs: systematic review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Publication bias: a brief review for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

A 6 month randomized, double blind, placebo controlled, multi-center trial of high dose atorvastatin on myocardial perfusion abnormalities by positron emission tomography in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Preoperative lipid control with simvastatin protects coronary artery bypass grafts from obstructive graft disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind t

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Effect of pravastatin on outcomes after cardiac transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrial-based or dual-chamber pacemaker: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

Validity of composite end points in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCQ165

21 January 2018

Identifiers

DOI

10.1093/QJMED/HCQ165

1 reference

31 July 2017

1 reference